Improvement in dermatomyositis-associated muscle disease with anifrolumab
Leila H. Shayegan, Katharina Shaw, Ged G. Wieschhoff, Nnenna Ezeh, Yoo Jung Kim, Neda Shahriari, Ellen Anshelevich, Lorena Acevedo, Avery LaChance, Fatma Dedeoğlu, Rochelle Castillo, Allen W. Ho, Ruth Ann Vleugels
Abstract
We describe radiological and symptomatic improvement in two patients with dermatomyositis with recalcitrant muscle disease following off-label treatment with anifrolumab, a monoclonal antibody targeting type I interferon receptor recently approved by the FDA and EMA for the treatment of systemic lupus erythematosus.
Topics & Concepts
DermatomyositisMedicineMonoclonalConnective tissue diseaseMuscle diseaseDermatologyLupus erythematosusMonoclonal antibodyDiseaseImmunologyAntibodyAutoimmune diseasePathologyInflammatory Myopathies and DermatomyositisImmunodeficiency and Autoimmune DisordersEosinophilic Disorders and Syndromes